Xconomy | Boston - Business + Technology in the Exponential Economy

Related Posts

Biotech, cancer, deforolimus

Ariad Gets $12.5M From Merck For Beginning Cancer Trial

Luke Timmerman 10/20/08

Ariad Pharmaceuticals, the Cambridge, MA-based developer of cancer drugs, said today it will receive a $12.5 million milestone payment from its partner, Merck, for beginning a mid-stage study of deforolimus for patients with advanced prostate cancer. The treatment, an oral pill, is being tested against other forms of cancer through the Merck partnership.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share:   Retweet Facebook Email

Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    
Xconomy network map Seattle Boston San Diego
national life-sciences startups

Most Popular Stories

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.